Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3497]

ENDURANCE trial shows no survival benefit for extended lenalidomide maintenance in Multiple Myeloma

ENDURANCE trial shows no survival benefit for extended lenalidomide maintenance in Multiple Myeloma

Have the clinical signs of a serious type of blood cancer changed?

Have the clinical signs of a serious type of blood cancer changed?

Immune cells use previously unknown pathway to eliminate AML

Immune cells use previously unknown pathway to eliminate AML

Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy

Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy

ECOG-ACRIN ENDURANCE trial findings provide the first randomised evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

ECOG-ACRIN ENDURANCE trial findings provide the first randomised evidence on the optimal duration of lenalidomide...

Immune ecotypes may explain multiple myeloma outcomes missed by disease staging

Immune ecotypes may explain multiple myeloma outcomes missed by disease staging

Combination treatment harnesses cellular recycling system to fight multiple myeloma

Combination treatment harnesses cellular recycling system to fight multiple myeloma

IU study finds obesity 'fuels' leukaemia, but a combo using popular weight-loss drugs may stop it

IU study finds obesity 'fuels' leukaemia, but a combo using popular weight-loss drugs may stop it

Novel microenvironment-targeted therapy for bone marrow recovery after injury

Novel microenvironment-targeted therapy for bone marrow recovery after injury

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

More from ecancer